Lisa K Jennings, PhD founded CirQuest Labs in 2008 as an extension of her successful translational research program as a faculty member at the University of Tennessee Health Science Center. An internationally recognized leader in anti-platelet and anticoagulant therapies, she has served on numerous industry scientific and clinical development advisory boards. She has been instrumental in assisting industry in the design and implementation of pre-clinical studies and clinical trials in the vascular biology field, including cardiology, vascular, inflammatory and metabolic diseases, hematology, diagnostics and medical device fields.
Dr. Jennings is also Director of the UTHSC Vascular Biology Center of Excellence and Professor of Medicine at the University of Tennessee Health Science Center (UTHSC) in Memphis, Tennessee. She has secondary appointments as Professor in the Departments of Molecular Sciences and Surgery as well as in the Joint Program of Biomedical Engineering at UTHSC and the University of Memphis. She is also the Director of the Tennessee-Arkansas-Mississippi (TAM) Clinical Research Consortium.
Dr. Jennings attended graduate school at UTHSC completing her doctoral research projects at St. Jude Children’s Research Hospital and the Gladstone Foundation Laboratories in San Francisco, CA. During her training she was instrumental in the isolation and characterization of the platelet GPIIb-IIIa receptor, the key integrin on platelets that mediates platelet thrombus formation. This effort resulted in the first member of the integrin superfamily to be isolated and characterized as a calcium- dependent heterodimer complex. She completed a postdoctoral fellowship at St. Jude Children’s Research Hospital, where she was a Leon Journey Fellow, and was appointed to the faculty of UTHSC in 1985.
Dr. Jennings has an established research program in the area of platelet and vascular smooth muscle cell biology, specifically the function of surface membrane receptors and associated signaling pathways. She has primarily focused on the biology of GPIIb-IIIa and its function on thrombus stability and platelet reactivity including shear induced platelet activation. She has internationally- recognized expertise in the development, study and evaluation of antiplatelet agents and anticoagulants, including the design and conduct of the pharmacodynamic assessment of these agents in preclinical/translational studies and clinical trials. Clinical trials with which she has been involved include IMPACT, IMPACT II, PRIDE, ESPRIT, and PROTECT trials of eptifibatide, PYRAMID (YM337), ORATOR, TIMI 15A and B, PICOLO (clopidogrel), TRA-PCI, ATLAS, TRACER and UTHSC investigator-initiated studies via the TAM Consortium.
Her other research efforts concentrate on vascular injury response and inflammation, particularly signaling pathways associated with neointimal hyperplasia and atherogenesis. In addition, she is a founding member of ARISTE Medical, LLC dedicated to improving the treatment of vascular disease and infections associated with implantable devices. Dr. Jennings is taking these years of experience and expertise in the field into product development services.